Engaging Newly Diagnosed Men About Cancer Treatment Options



Status:Recruiting
Conditions:Prostate Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any - 76
Updated:5/18/2018
Start Date:April 2016
End Date:August 2022
Contact:Patrice King-Lee, MS
Email:pking1@uic.edu
Phone:(312) 355-3726

Use our guide to learn which trials are right for you!

The Impact of a Gene Expression Profile on Treatment Choice and Outcome Among Minority Men Newly Diagnosed With Prostate Cancer: A Randomized Trial

This research is being done to better understand how a new lab test called the Oncotype DX
Prostate Cancer Assay may impact what treatment men decide to get and how they feel and think
about their choice of treatment. The study will compare men who receive this new lab test
with men who receive the usual counseling given to men after they get a new diagnosis of
prostate cancer. Prostate cancer is sometimes slow-growing and sometimes fast-growing.
Healthcare providers are searching for better ways to predict how each tumor will behave so
that each man can make a better decision about when to receive treatment. The Oncotype DX lab
test uses leftover prostate biopsy tissue to generate a Genomic Prostate Score (GPS). The GPS
is related to the risk of a fast-growing cancer being discovered if surgery is performed to
remove a man's prostate. The goal of this study is to find out if this test helps men when
they are deciding how their prostate cancer will be treated. Treatment options include
surgery to remove the prostate, radiation therapy, or an approach called "active
surveillance" in which there is no immediate therapy and the tumor is watched using prostate
specific antigen (PSA) tests and repeat biopsies.


Inclusion Criteria:

- Men with newly diagnosed prostate cancer who are categorized as Very Low, Low, or
Intermediate risk by NCCN criteria;

- Are age 76 or younger

Exclusion Criteria:

- Men who are categorized as High or Very High risk by NCCN criteria;

- Men who have already received counseling from their urologist about their treatment
options and have decided to undergo treatment, active surveillance, or watchful
waiting;

- Men age 77 or older
We found this trial at
3
sites
Chicago, Illinois 60612
Principal Investigator: Courtney MP Hollowell, MD
Phone: 312-864-5234
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2035 W Taylor St
Chicago, Illinois
(312) 996-4350
Principal Investigator: Peter H Gann, MD, ScD
Phone: 312-355-3726
University of Illinois at Chicago A major research university in the heart of one of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Chicago, Illinois 60612
Principal Investigator: Roohollah Sharifi, MD
Phone: 312-569-8961
?
mi
from
Chicago, IL
Click here to add this to my saved trials